Severe Asthma

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato